Literature DB >> 23334187

Tumor-associated macrophages as a prognostic parameter in multiple myeloma.

Elif Suyanı1, Gülsan Türköz Sucak, Nalân Akyürek, Sevinç Sahin, Nuran Ahu Baysal, Münci Yağcı, Rauf Haznedar.   

Abstract

The interaction between multiple myeloma (MM) cells and the bone marrow stroma constitutes the basis of myeloma pathogenesis and has led the way for the corresponding therapeutic strategies. The aim of this study is to evaluate tumor-associated macrophages (TAMs) which is an important element of bone marrow stroma and its prognostic relevance in newly diagnosed MM patients. We also wanted to determine the association between TAMs and microvessel density (MVD). Sixty-eight patients, who were diagnosed with MM at the Department of Hematology, Gazi University Hospital, between January 2000 and January 2011, were reviewed retrospectively. Tumor-associated macrophages were evaluated by staining with anti-CD68 and anti-CD163 monoclonal antibodies, and MVD was evaluated by factor VIII staining. Median age was 60 (range, 40-84) years with 36 males and 32 females. The number of both CD 68+ and CD 163+ cells had a negative impact on OS at 6 years (p = 0.013 vs. 0.036; p = 0.015 vs. 0.039) in univariate and multivariate analysis in which age, sex, ISS, the induction treatment, and response to induction treatment are included as variables. High-grade MVD was found to be associated with increased CD163+ cell count. In conclusion, TAMs seems to be a promising prognostic histopathological marker in newly diagnosed MM patients.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23334187     DOI: 10.1007/s00277-012-1652-6

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  39 in total

1.  Antibody-Dependent Cellular Phagocytosis by Macrophages is a Novel Mechanism of Action of Elotuzumab.

Authors:  Ahmed T Kurdi; Siobhan V Glavey; Natalie A Bezman; Amy Jhatakia; Jennifer L Guerriero; Salomon Manier; Michele Moschetta; Yuji Mishima; Aldo Roccaro; Alexandre Detappe; Chia-Jen Liu; Antonio Sacco; Daisy Huynh; Yu-Tzu Tai; Michael D Robbins; Jamil Azzi; Irene M Ghobrial
Journal:  Mol Cancer Ther       Date:  2018-04-13       Impact factor: 6.261

2.  Tumor-associated macrophages and extracellular matrix metalloproteinase inducer in prognosis of multiple myeloma.

Authors:  S Panchabhai; K Kelemen; G Ahmann; S Sebastian; J Mantei; R Fonseca
Journal:  Leukemia       Date:  2015-07-23       Impact factor: 11.528

Review 3.  Macrophages in multiple myeloma: key roles and therapeutic strategies.

Authors:  Khatora S Opperman; Kate Vandyke; Peter J Psaltis; Jacqueline E Noll; Andrew C W Zannettino
Journal:  Cancer Metastasis Rev       Date:  2021-01-06       Impact factor: 9.264

Review 4.  Macrophages in multiple myeloma: emerging concepts and therapeutic implications.

Authors:  Fotis Asimakopoulos; Jaehyup Kim; Ryan A Denu; Chelsea Hope; Jeffrey L Jensen; Samuel J Ollar; Ellen Hebron; Claire Flanagan; Natalie Callander; Peiman Hematti
Journal:  Leuk Lymphoma       Date:  2013-04-11

Review 5.  Preclinical validation of interleukin 6 as a therapeutic target in multiple myeloma.

Authors:  Timothy R Rosean; Van S Tompkins; Guido Tricot; Carol J Holman; Alicia K Olivier; Fenghuang Zhan; Siegfried Janz
Journal:  Immunol Res       Date:  2014-08       Impact factor: 2.829

Review 6.  Immunotherapeutic approaches to treat multiple myeloma.

Authors:  Mieke W H Roeven; Willemijn Hobo; Nicolaas Schaap; Harry Dolstra
Journal:  Hum Vaccin Immunother       Date:  2013-12-11       Impact factor: 3.452

Review 7.  Utilizing cell-based therapeutics to overcome immune evasion in hematologic malignancies.

Authors:  Chuang Sun; Gianpietro Dotti; Barbara Savoldo
Journal:  Blood       Date:  2016-05-20       Impact factor: 22.113

Review 8.  Immune responses in multiple myeloma: role of the natural immune surveillance and potential of immunotherapies.

Authors:  Camille Guillerey; Kyohei Nakamura; Slavica Vuckovic; Geoffrey R Hill; Mark J Smyth
Journal:  Cell Mol Life Sci       Date:  2016-01-22       Impact factor: 9.261

9.  BMI1 regulates multiple myeloma-associated macrophage's pro-myeloma functions.

Authors:  Danfeng Zhang; Jingcao Huang; Fangfang Wang; Hong Ding; Yushan Cui; Yan Yang; Juan Xu; Hongmei Luo; Yuhan Gao; Ling Pan; Yu Wu; Yuping Gong; Liping Xie; Zhigang Liu; Ying Qu; Li Zhang; Weiping Liu; Wenyan Zhang; Sha Zhao; Qing Yi; Ting Niu; Yuhuan Zheng
Journal:  Cell Death Dis       Date:  2021-05-15       Impact factor: 8.469

10.  CD4+ T-cell killing of multiple myeloma cells is mediated by resident bone marrow macrophages.

Authors:  Ole Audun W Haabeth; Kjartan Hennig; Marte Fauskanger; Geir Åge Løset; Bjarne Bogen; Anders Tveita
Journal:  Blood Adv       Date:  2020-06-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.